VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients amenable to exon 53 skipping. Accelerated approval is based on an increase in dystrophin. There is an ongoing study to confirm the clinical benefit of VILTEPSO.
833-NSSUPRT (833-677-8778)
Monday–Friday, 8 AM-8 PM ET
With NS Support, NS Pharma is fully committed to providing ongoing support to patients, their caregivers, and healthcare professionals who treat patients with DMD.
LEARN MORE ABOUT NS SUPPORTVILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
For more information about VILTEPSO, see full Prescribing Information.
For more information about VILTEPSO, see full Prescribing Information.